Philadelphia Trust Co. Makes New $589,000 Investment in CryoPort, Inc. (NASDAQ:CYRX)

Philadelphia Trust Co. acquired a new stake in CryoPort, Inc. (NASDAQ:CYRX) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 96,836 shares of the company’s stock, valued at approximately $589,000. Philadelphia Trust Co. owned 0.19% of CryoPort at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of CryoPort by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock valued at $476,000 after buying an additional 15,036 shares during the period. Graham Capital Management L.P. boosted its holdings in CryoPort by 24.9% in the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company’s stock valued at $221,000 after acquiring an additional 5,667 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of CryoPort during the 4th quarter worth approximately $51,000. ProShare Advisors LLC bought a new position in shares of CryoPort during the 4th quarter worth approximately $95,000. Finally, CWM LLC boosted its holdings in shares of CryoPort by 1,437.0% during the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock worth $69,000 after buying an additional 10,591 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Stock Performance

NASDAQ:CYRX opened at $8.61 on Friday. The business has a 50 day moving average of $7.44 and a 200 day moving average of $6.61. The company has a market capitalization of $431.08 million, a price-to-earnings ratio of 6.47 and a beta of 1.88. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $9.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 5.24.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The company had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. On average, sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CYRX. Leerink Partners upgraded CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target on the stock in a report on Wednesday, August 6th. Morgan Stanley cut their target price on CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. KeyCorp upgraded CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a report on Wednesday, August 6th. Finally, Stephens assumed coverage on CryoPort in a research note on Tuesday, July 22nd. They set an “overweight” rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.00.

Insider Activity at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the business’s stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the transaction, the director directly owned 92,328 shares of the company’s stock, valued at approximately $668,454.72. The trade was a 30.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Edward J. Zecchini sold 51,500 shares of the business’s stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total transaction of $352,260.00. Following the transaction, the insider directly owned 90,411 shares in the company, valued at approximately $618,411.24. The trade was a 36.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 490,447 shares of company stock worth $3,337,198. 10.00% of the stock is currently owned by insiders.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.